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OBJECTIVE: To project the health and economic conse-
quences associated with a prophylactic type-speciﬁc HPV-
16/18 vaccine in the setting of a cervical cancer screening
program. METHODS: A computer-based model of 
the natural history of cervical cancer that incorporates 
the type-speciﬁc HPV distribution within precancerous
lesions and cancer was used to estimate cancer incidence
and mortality, quality-adjusted life years (QALY), lifetime
costs, and incremental cost-effectiveness ratios associated
with different cancer prevention policies consisting of
vaccination, screening, and combined vaccination/screen-
ing strategies. Strategies included (1) no vaccination and
no screening; (2) no vaccination and cytology screening
every 1, 2, 3, 4, and 5 years; (3) vaccination and cytol-
ogy screening every 1, 2, 3, 4, and 5 years. Screening
strategies included conventional and liquid-based cytol-
ogy initiated at ages 18, 21, 25, or 30. We assumed vac-
cination occurred at age 12 and was 90% effective in
reducing the probability of acquiring persistent infection
with HPV 16/18, but evaluated the impact of alternative
assumptions about vaccine efﬁcacy and waning immu-
nity. RESULTS: Vaccination at age 12 followed by trien-
nial cytology screening beginning at age 30 provided
reductions in cervical cancer mortality above those pro-
vided by annual conventional cytology and had an incre-
mental cost-effectiveness ratio of below $50,000 per
QALY compared to the next best strategy of vaccination
and triennial cytology screening beginning at age 35.
These results were stable over a range of vaccine efﬁca-
cies (60% to 100%) but sensitive to the degree to which
vaccination effect persists over time. CONCLUSIONS: A
prophylactic vaccine that prevents persistent HPV 16/18
infection can be expected to signiﬁcantly reduce HPV-
16/18-associated high-grade lesions and cervical cancer
even in a setting of cytology screening. A program of vac-
cination that permits a later age of screening initiation
and a less frequent screening interval is likely to be a cost-
effective use of health care resources.
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ECONOMIC IMPACT OF ANTIRETROVIRAL
DRUG PRICE REDUCTIONS IN NINE LATIN
AMERICAN COUNTRIES
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OBJECTIVE: A recent agreement to lower the price of
antiretroviral drugs in several Latin American countries
will decrease the cost of treating HIV/AIDS patients to
levels similar to those in Brazil’s established, prototypical
universal access program. This analysis estimates the
likely economic impact of these price reductions in nine
countries (Argentina, Bolivia, Chile, Colombia, Ecuador,
Mexico, Peru, Uruguay, Venezuela) compared to the eco-
nomic impact afforded by Brazil. METHODS: The cost
of two- and three-drug combination antiretroviral was
estimated by applying 2000 Brazilian drug prices (in U.S.
dollars). These costs were multiplied by each country’s
estimated HIV/AIDS population and by the rate of cov-
erage given by Brazil’s universal access program (14.4%
of the HIV/AIDS population). The ratio of these esti-
mated drug costs to gross domestic product (GDP) was
determined to measure each country’s relative ability to
afford treatment. Similar calculations were made to
include cost savings from averted hospitalizations due 
to antiretroviral care. RESULTS: Mexico, Colombia, and
Argentina have the largest HIV/AIDS populations, and
thus, the highest estimated annual drug costs ($91.8
million, $86.1 million, and $79.5 million, respectively).
Bolivia and Uruguay have the lowest costs at $2.8 million
and $3.8 million, respectively. Compared to Brazil’s drug-
cost-to-GDP ratio (0.026%), 6 countries are estimated to
have lower ratios. Chile and Mexico have the lowest
ratios (0.08% and 0.010%, respectively). Only Colombia
(0.032%), Ecuador (0.029%), and Venezuela (0.026%)
have higher ratios equal to or higher than Brazil’s. Savings
from averted hospitalizations reduced overall costs
between 33% and 52% when triple-combination therapy
is included in the program. CONCLUSIONS: For pro-
grams including triple-combination therapy, only Colom-
bia and Ecuador may ﬁnd the new drug program less
affordable than Brazil. Countries with lower drug-cost-
to-GDP ratios should be able to cover a higher percent-
age of patients than Brazil.
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THE IMPACT OF COST-EFFECTIVENESS OF
COUNTRY SPECIFIC APPLICATION—THE CASE
OF DROTRECOGIN ALFA (ACTIVATED) IN
SEVERE SEPSIS
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OBJECTIVES: The purpose of this study was to assess
the cost-effectiveness of drotrecogin alfa (activated)
(DAA) as an adjunct to standard therapy compared to
standard therapy alone for Swedish patients with severe
sepsis by using 1) country speciﬁc cost and resource data
compared to 2) exchange rate transferring of a UK model
application based on the results from the clinical trial and
UK treatment patterns. METHODS: In the PROWESS
trial DAA has been found to decrease the all cause 28-
day mortality in adult patients with severe sepsis. A C/E
model was developed for estimating costs and outcomes
and could be applied taking account of local treatment
